key: cord-0797681-mwvp447n
authors: Debliquis, Agathe; Harzallah, Inès; Mootien, Joy Y.; Poidevin, Antoine; Labro, Guylaine; Mejri, Amira; Lamarque, Mathilde; Kuteifan, Khaldoun; Drénou, Bernard
title: Haemophagocytosis in bone marrow aspirates in patients with COVID‐19
date: 2020-06-12
journal: Br J Haematol
DOI: 10.1111/bjh.16860
sha: 7bd9678167a04f3b55c0378cca6c5a62e5d32778
doc_id: 797681
cord_uid: mwvp447n

nan

A 78-year-old man with haemorrhagic signs (epistaxis and purpura) presented with severe thrombocytopenia, lymphopenia and circulating neutrophil precursors. A bone marrow aspirate showed increased plasma cells and an increase in pleomorphic megakaryocytes, consistent with peripheral thrombocytopenia. A few macrophages showing haemophagocytosis were also revealed ( Fig 1A) . Considering the outbreak of COVID-19, 1,2 the combination of thrombocytopenia, lymphopenia and neutrophil precursors led to consideration and detection of SARS-CoV-2, although the patient did not have fever, cough, dyspnoea, diarrhoea, myalgia or headache. The diagnosis was confirmed by reverse transcriptase-polymerase chain reaction (RT-PCR) assay and chest X-ray (CXR). Apart from thrombocytopenia and haemophagocytosis, this patient did not have other features of secondary haemophagocytic lymphohistiocytosis (sHLH). Clinical and laboratory features of the H-score 3 were not met (Table I) . Numerous large megakaryocytes in the bone marrow aspirate and the presence of platelet antibodies led to a diagnosis of autoimmune thrombocytopenic purpura (ITP), potentially related to COVID-19. 4 The platelet count increased after treatment with intravenous immunoglobulin (from 6 to 87 9 10 9 /l in 5 days). Corticosteroids were avoided in the context of COVID-19. 5 Two other patients with severe COVID-19 confirmed by RT-PCR also had haemophagocytosis demonstrated in a bone marrow aspirate performed for cytopenia (Fig 1B,C) . One of them (patient 2) was a 67-year-old obese woman with worsening of her general state, cough and fever, with a known SARS-CoV-2 contact. On admission, she had dyspnoea and tachycardia. CXR showed diffuse bilateral correspondence pulmonary infiltrates, and SARS-CoV-2 infection was confirmed by RT-PCR. A bone marrow aspirate also revealed increased pleomorphic megakaryocytes and increased plasma cells, but with more prominent haemophagocytosis in this case ( Fig 1B) . Interestingly, haemophagocytosis often involved platelets. The H-score (Table I) showed a low probability of sHLH (<1%). The patient died of refractory acute respiratory distress syndrome (ARDS). Patient 3 was a 63year-old obese man with the same symptoms as patient 2 at disease onset. He was hospitalised in the intensive care unit for respiratory and renal failure. A bone marrow aspirate performed for cytopenia showed, once again, increased pleomorphic megakaryocytes, increased plasma cells and numerous haemophagocytic macrophages (Fig 1C) . The high Hscore probability of 92% as well as the multiorgan failure leading to death confirmed a sHLH diagnosis in this setting.

COVID-19 may show varying presentation. 6 Our report highlights the presence of haemophagocytosis in these three cases of COVID-19 presenting with different clinical features and severity: one ITP, one ARDS and one sHLH. Haemophagocytosis is neither necessary nor mandatory for the diagnosis of sHLH. 7 The H-score, 3 including underlying immunoinsufficiency, body temperature, organomegaly, cytopenias, serum ferritin, triglycerides, fibrinogen and aspartate aminotransferase should be taken into account. Cytopenia, hyperferritinaemia and coagulopathy are described in many severe COVID-19 pneumonia cases, suggesting that a subgroup of cases may have a macrophage activation syndrome. 8 In COVID-19, the lungs are mainly involved, and the classical organomegaly pattern of sHLH is uncommonly reported. 9,10 Paradoxically, we found haemophagocytosis in the bone marrow aspirates of the two patients without features of sHLH. One of these patients did not have evidence of inflammation (low C-reactive protein; see Table I ). The macrophage activation in the bone marrow could partially explain the cytopenia in patient 2, with severe thrombocytopenia and activated macrophages engulfing mainly platelets. Furthermore, an autoimmune process may be involved, as in patient 1 with ITP. Apart from these pathophysiological considerations, in laboratory practice haemophagocytosis in the bone marrow is usually observed in infection, autoimmune disease, myeloproliferative neoplasms, bone marrow failure and haemolysis. 11 Henceforth, whatever the clinical presentation, SARS-CoV-2 infection should be considered among the causes when haemophagocytosis is observed, probably even outside the context of a pandemic. 

A novel coronavirus from patients with pneumonia in China

Development and validation of the hscore, a score for the diagnosis of reactive hemophagocytic syndrome

Andr es E. Immune thrombocytopenic purpura in a patient with Covid-19

The effect of corticosteroid treatment on patients with coronavirus infection: a systematic review and meta-analysis

Clinical characteristics of coronavirus disease 2019 in China

Diagnostic evaluation of patients with suspected haemophagocytic lymphohistiocytosis

The role of cytokines including interleukin-6 in COVID-19 induced pneumonia and macrophage activation syndrome-like disease

Pathological study of the 2019 novel coronavirus disease (COVID-19) through postmortem core biopsies

Pathological findings of COVID-19 associated with acute respiratory distress syndrome

Advances in understanding the pathogenesis of HLH